TABLE 2.
Population pharmacokinetic parameters of FTC from the final model for HIV-infected pregnant women (n = 38) after receiving 400 mg of FTC at the start of the labor and for their neonates (n = 32) enrolled in the TEmAA ANRS 12109 trial, step 1a
| Parameter | Estimate (% RSE) |
|---|---|
| Structural model: | |
| ka (h−1) | 0.54 (11) |
| CL/F (liter/h) | 23.2 (4) |
| V1/F (liter) | 127 (7) |
| Q/F (liter/h) | 6.04 (10) |
| V2/F (liter) | 237 (15) |
| k1F (h−1) | 0.289 (13) |
| kF1 (h−1) | 0.383 (13) |
| kF0 (h−1) | 0.0653 (7) |
| Statistical model: | |
| ωka (%) | 61 (29) |
| ωCL/F (%) | 17 (34) |
| ωkF0 (%) | 30 (35) |
| σMother (%) | 45 (14) |
| σcord (%) | 43 (24) |
| σneonate (%) | 33 (27) |
% RSE, relative standard error (standard error of estimate/estimate × 100); ka, absorption rate constant; CL/F, maternal apparent elimination clearance from the central compartment; V1/F, apparent volume of distribution of the central maternal compartment; Q2/F, apparent maternal intercompartmental clearance; V2/F, apparent volume of distribution of the peripheral maternal compartment; k1F, mother-to-fetus transfer rate constant; kF1, fetus-to-mother transfer rate constant; kF0, neonate elimination rate constant; σ, residual variability estimates (coefficient of variation of residual variability [%]); and ω, interindividual variability estimates (coefficient of variation of intersubject variability [%]).